Table 3. Comparison of treatment patterns and response to macrolides in children with Mycoplasma pneumoniae pneumonia according to macrolide sensitivity.
| Variable | MSMP (n=12) | MRMP (n=82) | Total (n=94) | P value |
|---|---|---|---|---|
| Total duration of antibiotics (day) | 12.7±6.4 | 13.5±5.2 | 13.4±5.3 | 0.632 |
| Total number of antibiotics used (day) | 1.6±0.7 | 2.1±0.8 | 2.00±0.8 | 0.046* |
| Initially prescribed antibiotics | 0.671 | |||
| Nonmacrolide | 2/10 (20.0) | 24/76 (31.6) | 26/86 (30.2) | |
| Azithromycin | 6/10 (60.0) | 23/76 (30.3) | 29/86 (33.7) | |
| Clarithromycin | 2/10 (20.0) | 24/76 (31.6) | 26/86 (30.2) | |
| Roxithromycin | 0/10 (0) | 5/76 (6.5) | 5/86 (5.8) | |
| Number of changes in antibiotics from macrolide to tetracycline or fluoroquinolone | 3/12 (25.0) | 24/82 (29.3) | 27/94 (28.7) | 0.833 |
| Antibiotics changes within the macrolide | 2/11 (18.2) | 33/79 (41.8) | 35/90 (38.9) | 0.133 |
| Time to defervescence after initiation of the first macrolide (day) | 2.8±3.1 (0–9) | 4.9±3.3 (0–15) | 4.7±3.3 | 0.039* |
Values are presented as a mean±standard deviation (SD), number (%), mean±SD (range),
Nonmacrolide antibiotics included β-lactam and cephalosporin.
MRMP, macrolide-resistant Mycoplasma pneumoniae; MSMP, macrolide-susceptible Mycoplasma pneumoniae.
*P<0.05.